Renascience

Renascience Financing Cash Flow

The Net Financing Cash Flow of Renascience (4889.T) as of Nov 19, 2026 is 1.89 B JPY. In the previous year, Net Financing Cash Flow was -52.18 M JPY — a change of -3,729.98% (higher).

Financing Cash Flow

1.89 BJPY

YoY

-3,729.98%

Last updated:

Net Financing Cash Flow of Renascience is 2026 1.89 B JPY. Net Financing Cash Flow of Renascience was 2025 -52.18 M JPY. It decreases by -3,729.98% higher compared to the previous year.

The Renascience Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2020
380.00 M JPY
Jan 1, 2021
135.65 M JPY
Jan 1, 2022
1.59 B JPY
Jan 1, 2023
110.37 M JPY
Jan 1, 2024
46.50 M JPY
Jan 1, 2025
-52.18 M JPY
Jan 1, 2026
1.89 B JPY
The Renascience Financing Cash Flow history
YEARFinancing Cash FlowYoY
1.89 BJPY-3,729.98%
-52.18 MJPY-212.22%
46.50 MJPY-57.87%
110.37 MJPY-93.07%
1.59 BJPY+1,073.36%
135.65 MJPY-64.30%
380.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Net Financing Cash Flow of Renascience is 1.89 B JPY in 2026.

Net Financing Cash Flow of Renascience changed from -52.18 M JPY to 1.89 B JPY, representing a -3,729.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Renascience since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience